Dexanabinol as a treatment for traumatic brain injury: Will another therapeutic promise be broken?

Critical Care Medicine

Volumn 30, Issue 3, 2002, Pages 710-711

  Bedell, Eric A ^a   Prough, Donald S ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Cannabinoids; Phase II clinical trials; Traumatic brain injury

Indexed keywords

DEXANABINOL; PLACEBO;

ANTIOXIDANT ACTIVITY; BRAIN INJURY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EDITORIAL; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INTRACRANIAL HYPERTENSION; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0036189915     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200203000-00041     Document Type: Editorial

References (19)

1. Dexanabinol (HU-211) in the treatment of severe closed head injury: A randomized, placebo-controlled phase II clinical trial
2. Enantiomeric cannabinoids: Stereospecificity of psychotropic activity
3. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker
4. Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist
5. Cytokine production in the brain following closed head injury: Dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant
6. HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy
7. HU-211, a novel noncompetitive N-methyl-D-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat
8. Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat
9. Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers
10. Development of HU-211 as a neuroprotectant for ischemic brain damage
11. Impact of ICP instability and hypotension on outcome in patients with severe head trauma
12. Early and late systemic hypotension as a frequent and fundamental source of cerebral ischemia following severe brain injury in the traumatic coma data bank
13. Postischemic moderate hypothermia inhibits CA1 hippocampal ischemic neuronal injury
14. Marked protection by moderate hypothermia after experimental traumatic brain injury
15. A phase II study of moderate hypothermia in severe brain injury
16. Treatment of traumatic brain injury with moderate hypothermia
17. Lack of effect of induction of hypothermia after acute brain injury
18. Clinical neuro-protection trials in severe traumatic brain injury: Lessons from previous studies
19. Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoreticai considerations